Novo Nordisk has obtained worldwide rights to EpiDestiny’s sickle cell disease treatment EPI01. The disease-modifying therapy, consisting of decitabine…
Articles by Margarida Azevedo, MSc
The European Medicines Agency recently granted orphan drug status to Sancilio Pharmaceuticals’ Altemia for the treatment of sickle…
The European Medicines Agency (EMA) has signaled that it is ready to begin reviewing Emmaus Life Sciences’ Xyndari as a…
Gamida Cell recently presented updated data from its ongoing Phase 1/2 clinical trial on an experimental alternative to bone marrow…
Emmaus Life Sciences has reached an agreement with the Centers for Medicare and Medicaid Services that will allow coverage of…
England’s National Health Service (NHS) has selected 138 entrepreneurs to design and deliver new technological solutions for healthcare challenges…
The U.S. Food and Drug Administration (FDA) approved Endari (L-glutamine) last summer, but now the medicine is available by…
Emmaus Life Sciences has developed a sickle cell disease therapy that the United States has approved but regulators in much of…
Prolong Pharmaceuticals has completed enrolling patients in an ongoing Phase 2 clinical trial of  Sanguinate, a treatment for the…
Vertex Pharmaceuticals and CRISPR Therapeutics recently announced a joint collaboration to co-develop and co-commercialize CTX001 as a gene-editing…